{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:03:12Z","timestamp":1792008192010,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007724","name":"Wuhan University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejps.2021.105864","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:35:40Z","timestamp":1620297340000},"page":"105864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Yaowen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105864_bib0001","first-page":"326","article-title":"New adjuvant trial designs in colon cancer","volume":"11","author":"Leal","year":"2015","journal-title":"Curr. Colorectal Cancer. Rep."},{"key":"10.1016\/j.ejps.2021.105864_bib0002","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"Ca Cancer J. Clin."},{"key":"10.1016\/j.ejps.2021.105864_bib0003","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Pox C P. colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2021.105864_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-med-051513-102539","article-title":"Recent therapeutic advances in the treatment of colorectal cancer","volume":"66","author":"Ciombor","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejps.2021.105864_bib0005","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1097-0142(19941001)74:7+<2154::AID-CNCR2820741725>3.0.CO;2-G","article-title":"The role of radiation therapy in the treatment of colorectal cancer. Implications for the older patient","volume":"74","author":"Farniok","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2021.105864_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10147-015-0801-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer","volume":"20","author":"Watanabe","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2021.105864_bib0007","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","article-title":"Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial","volume":"15","author":"Yong","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2021.105864_bib0008","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.21873\/anticanres.11614","article-title":"Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer","volume":"37","author":"Inadomi","year":"2017","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.ejps.2021.105864_bib0009","first-page":"893","article-title":"Low dose of resveratrol enhanced immune response of mice","volume":"23","author":"Feng","year":"2002","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2021.105864_bib0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12885-015-1630-1","article-title":"Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer","volume":"15","author":"Komatsu","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2021.105864_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-12-108","article-title":"A phase \u0399I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)","volume":"12","author":"Hazama","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejps.2021.105864_bib0012","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1586\/14737140.2015.1102063","article-title":"Bevacizumab in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer","volume":"15","author":"Grapsa","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejps.2021.105864_bib0013","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2021.105864_bib0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison to the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2021.105864_bib0015","first-page":"S38","article-title":"Clinical Management of Oxaliplatin-Associated Neurotoxicity","volume":"5","author":"Grothey","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejps.2021.105864_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186250","article-title":"Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: phenotypic and genotypic insights","volume":"12","author":"Marmiroli","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2021.105864_bib0017","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/ERC-13-0171","article-title":"Resveratrol and Cancer: focus on In Vivo Evidence","volume":"21","author":"Carter","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejps.2021.105864_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.200900437","article-title":"Resveratrol bioavailability and toxicity in humans","volume":"54","author":"Cottart","year":"2010","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejps.2021.105864_bib0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2014.11.049","article-title":"Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growthin vitro and in vivo","volume":"478","author":"Jung","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105864_bib0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/mnfr.201200766","article-title":"Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death","volume":"57","author":"Aires","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejps.2021.105864_bib0021","first-page":"1621","article-title":"Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity","volume":"19","author":"Saiko","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejps.2021.105864_bib0022","doi-asserted-by":"crossref","first-page":"10964","DOI":"10.1021\/jf202846b","article-title":"Inhibitory Effects of Resveratrol and Pterostilbene on Human Colon Cancer Cells: a Side-by-Side Comparison","volume":"59","author":"Nutakul","year":"2011","journal-title":"Journal of Agricultural & Food Chemistry"},{"key":"10.1016\/j.ejps.2021.105864_bib0023","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1471-2407-10-238","article-title":"Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R\/Wnt and activation of p53 signaling pathways","volume":"10","author":"Vanamala","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2021.105864_bib0024","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3892\/ijo.2017.3859","article-title":"Different effect of resveratrol to induction of apoptosis depending on the type of human cancer cells","volume":"50","author":"Takashina","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejps.2021.105864_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tifs.2014.05.003","article-title":"Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues","volume":"38","author":"Davidov-Pardo","year":"2014","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.ejps.2021.105864_bib0026","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/10717544.2014.924167","article-title":"Preparation and in vitro\/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles","volume":"23","author":"Zu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2021.105864_bib0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.carbpol.2017.07.058","article-title":"Preparation and biological activity studies of resveratrol loaded ionically cross-linked chitosan-TPP nanoparticles","volume":"175","author":"Wu","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejps.2021.105864_bib0028","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1021\/mp400342f","article-title":"Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly (D, L-lactic-co-glycolic acid)-poly (ethylene glycol) blend for prostate cancer treatment","volume":"10","author":"Sanna","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.105864_bib0029","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijpharm.2013.05.007","article-title":"Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma","volume":"452","author":"Bu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105864_bib0030","first-page":"795","article-title":"Nanoscale drug delivery systems and the blood-brain barrier","volume":"9","author":"Alyautdin","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2021.105864_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1615\/CritRevBiomedEng.v40.i1.20","article-title":"Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities","volume":"40","author":"Waite","year":"2012","journal-title":"Crit. Rev. Biomed. Eng."},{"key":"10.1016\/j.ejps.2021.105864_bib0032","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejps.2021.105864_bib0033","doi-asserted-by":"crossref","first-page":"6b00437","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nano-drug delivery: is the enhanced permeability and retention (EPR) effect sufficient for curing cancer","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2021.105864_bib0034","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target","volume":"4","author":"Kobayashi","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.ejps.2021.105864_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond","volume":"164","author":"Maeda","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105864_bib0036","doi-asserted-by":"crossref","first-page":"12499","DOI":"10.1038\/ncomms12499","article-title":"Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2021.105864_bib0037","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nano.2009.03.002","article-title":"Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer","volume":"6","author":"Jain","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2021.105864_bib0038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semcancer.2012.05.001","article-title":"Immunosuppression in the tumor microenvironment: where are we standing","volume":"22","author":"Umansky","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejps.2021.105864_bib0039","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CJI.0000000000000011","article-title":"TGF-\u03b21 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression","volume":"37","author":"Nakamura","year":"2014","journal-title":"J. Immunotherapy"},{"key":"10.1016\/j.ejps.2021.105864_bib0040","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.4049\/jimmunol.1103040","article-title":"Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs","volume":"188","author":"Kim","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejps.2021.105864_bib0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbi.2011.07.236","article-title":"Role of resveratrol-induced CD11b+ Gr-1+ myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3+ T cells and amelioration of chronic colitis in IL-10\u2212\/\u2212 mice","volume":"26","author":"Singh","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejps.2021.105864_bib0042","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1476-5381.2012.02063.x","article-title":"Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury","volume":"167","author":"Rieder","year":"2012","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:19Z","timestamp":1760529559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":42,"alternative-id":["S0928098721001652"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105864","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105864"}}